Bristol-Myers Squibb
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after Q3 earnings topped...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal port...
Latest News
2 days ago · seekingalpha.com
Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)Bristol-Myers Squibb is downgraded to 'Hold' as its current valuation appears optimistic ahead of looming patent cliffs. BMY's Growth Portfolio now comprises ~59% of revenues, with 8 medicines annualizing above $1 billion, partially offsetting legacy portfolio declines. DCF analysis values BMY at $61.19 per share, nearly matching the current price, highlighting limited upside even with near flat forward revenue growth.
3 days ago · zacks.com
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline ProgressBMY raises its 2026 revenue outlook on strong Growth Portfolio sales, even as earnings pressure, patent expirations and drug launch challenges remain in focus.
3 days ago · zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarThe Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
3 days ago · marketbeat.com
Bristol Myers Squibb Q3 Earnings Call HighlightsBristol Myers Squibb NYSE: BMY raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a series of clinical readouts and manufacturing investments intended to support its next generation of launches.
3 days ago · fool.com
Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings ReactionBristol Myers Squibb's Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion. Adjusted EPS fell 17% to $1.35, but mostly because of deal accounting, not a weaker core business.
3 days ago · zacks.com
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on OutlookBristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
3 days ago · seekingalpha.com
Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call TranscriptBristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript
4 days ago · zacks.com
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 EarningsThe headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
4 days ago · zacks.com
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesBristol Myers Squibb (BMY) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.63 per share a year ago.
4 days ago · wsj.com
Bristol Myers Squibb Raises Outlook as Quarterly Revenue RisesBristol Myers Squibb raised its full-year revenue outlook due to higher third-quarter revenue.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BMY